Published in Healthcare Finance, Tax and Law Weekly, December 13th, 2006
"The third quarter was marked by significant progress with the clinical development of our luteinizing hormone-releasing hormone (LHRH) antagonist compound, ozarelix, for which we disclosed positive phase II results in both prostate cancer and benign prostatic hyperplasia," said Gilles Gagnon, Aeterna Zentaris' president and CEO. "These very encouraging results enable us to pursue ozarelix's clinical development in both indications, moving forward with an ongoing phase IIb trial in prostate cancer as well as the potential to initiate a late-stage...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.